Enliven Therapeutics Inc
Enliven Therapeutics Inc (ELVN) Historical Volatility
ELVN's 30 day historical volatility is 56.89%, in the 47th percentile of readings over the past year. This is an average percentile, meaning Enliven Therapeutics Inc shares have moved roughly in line with their typical range. ELVN's 30 day implied volatility sits at 58.84%, with an IV Rank of 12.70%, leaving IV 1.95 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 20, 2026.
Read more
Tracking ELVN historical volatility helps you see how much Enliven Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ELVN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ELVN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ELVN's 30 day historical volatility, or ELVN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ELVN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 20, 2026
As of Nov 20, 2026
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →